KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Shares Outstanding (2018 - 2025)

ClearPoint Neuro's Shares Outstanding history spans 9 years, with the latest figure at $24.5 million for Q2 2022.

  • For Q2 2022, Shares Outstanding rose 9.67% year-over-year to $24.5 million; the TTM value through Jun 2022 reached $24.5 million, up 9.67%, while the annual FY2021 figure was $23.7 million, 38.82% up from the prior year.
  • Shares Outstanding for Q2 2022 was $24.5 million at ClearPoint Neuro, up from $23.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $24.5 million in Q2 2022 and bottomed at $10.8 million in Q1 2018.
  • The 5-year median for Shares Outstanding is $15.5 million (2020), against an average of $16.7 million.
  • The largest annual shift saw Shares Outstanding rose 2.23% in 2019 before it surged 43.91% in 2021.
  • A 5-year view of Shares Outstanding shows it stood at $11.0 million in 2018, then surged by 38.27% to $15.2 million in 2019, then rose by 11.9% to $17.0 million in 2020, then soared by 38.82% to $23.7 million in 2021, then rose by 3.44% to $24.5 million in 2022.
  • Per Business Quant, the three most recent readings for CLPT's Shares Outstanding are $24.5 million (Q2 2022), $23.7 million (Q1 2022), and $23.7 million (Q4 2021).